The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments. Rare / orphan diseases, as the name suggests, are those diseases which are relatively infrequent in occurrence. The prevalence and adversity of these ailments has gained significant attention in the global healthcare industry. The enactment of the Orphan Drugs Act in the US and EU emerged as ground breaking and provided the necessary support...

The oral thin films market, valued at USD 4.2 billion in 2024, is projected to grow to USD 4.5 billion in 2025 and USD 10.2 billion by 2035, representing a CAGR of 8.4% during the forecast period. Oral drug delivery technologies form an integral part of the pharmaceutical industry. From the conventional tablets / capsules to modern-day fast disintegrating and rapidly acting tablets / films, the market has come a long way. Lower bioavailability of oral solid drugs, inconvenience of administering...

The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

A significant proportion of the world

Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously prescribed over the last 25 years. Statins, though the mainstay therapy for lowering cholesterol, have been associated with some adverse events. These have deterred their use in a subset of population termed as

Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). However, the high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. Notably, there are specific opportunities which remain to be tapped in...

With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. In fact, tn the US alone, the economic burden of dry eye totals USD 3.84 billion in direct annual health care costs. After including the indirect costs of lost productivity, the societal burden of dry eye rises to USD 55.4 billion annually in t...